Human peripheral blood Vα24+ Vβ11+ NKT cells expand following administration of α-galactosylceramide-pulsed dendritic cells

Vox Sanguinis

Volumn 83, Issue 3, 2002, Pages 250-253

  Okai, M ^a   Nieda, Mie ^b,c   Tazbirkova, A ^a   Horley, D ^a   Kikuchi, A ^b   Durrant, S ^a   Takahashi, T ^d   Boyd, A ^a   Abraham, R ^a   Yagita, H ^e   Juji, T ^b   Nicol, A ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b JAPANESE RED CROSS MEDICAL CENTER   (Japan)

^c MEDINET Co Ltd   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

GalactosylCeramide; Autoimmune diseases; Dendritic cells; Human; NKT cells; Tumour immunity

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; GALACTOSYLCERAMIDE; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ALPHA GALACTOSYLCERAMIDE PULSED DENDRITIC CELL; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; DENDRITIC CELL; DRUG EFFICACY; DRUG PULSE THERAPY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEVER; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INFUSION; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MALAISE; METASTASIS; NATURAL KILLER CELL; PHENOTYPE; PRIORITY JOURNAL;

BLOOD CELLS; CELL DIVISION; DENDRITIC CELLS; FLOW CYTOMETRY; GALACTOSYLCERAMIDES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; LYMPHOCYTE COUNT; NEOPLASMS; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 0038052875     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1423-0410.2002.00217.x     Document Type: Article

References (10)

1. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K, Ueno H, Nakagawa R, Sato H, Kondo E, Koseki H, Taniguchi M: CD1d-restricted and TCR-mediated activation of Valpha 14 NKT cells by glycosylceramides. Science 1997; 278:1626-1629
2. Morita M, Motoki K, Akimoto K, Natori T, Sakai T, Sawa E, Yamaji K, Koezuka Y, Kobayashi E, Fukushima H: Structure-activity relationship of alpha-galactosylceramides against B16-bearing mice. J Med Chem 1995; 38:2176-2187
3. Nakagawa R, Motoki K, Ueno H, Iijima R, Nakamura H, Kobayashi E, Shimosaka A, Koezuka Y: Treatment of hepatic metastasis of the colon26 adenocarcinoma with an alpha-galactosylceramide, KRN7000. Cancer Res 1998; 58:1202-1207
4. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Sato H, Kondo E, Harada M, Koseki H, Nakayama T, Tanaka Y, Taniguchi M: Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells. Proc Natl Acad Sci USA 1998; 95:5690-5693
5. Toura I, Kawano T, Akutsu Y, Nakayama T, Ochiai T, Taniguchi M: Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha-galactosylceramide. J Immunol 1999; 163:2387-2391
6. + NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin Immunol 2001;100:144-148
7. Spada FM, Koezuka Y, Porcelli SA: CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells. J Exp Med 1998; 188:1529-1534
8. + NK cells in vitro. J Immunol 2000; 165:1659-1664
9. Giaccone G, Punt C, Ando Y, Ruijter R, Nishi N, Peters M, von Blomberg B, Scheper RJ, Roelvink M, Beijnen J, Zwierzina H, Pinedo H: KRN7000, an NKT cell enhancer, in patients with solid tumors - A phase I study of the EORTC BTDG. Proc Am Soc Clin Oncol 2000; 19:1871 (Abstract)
10. Nieda M, Nicol A, Koezuka Y, Kikuchi A, Takahashi T, Nakamura H, Furukawa H, Yabe T, Ishihara Y, Tadokoro K, Juji T: Activation of human Valpha 24NKT cells by α-glycosylceramide in a CD1d-restricted and Valpha24 TCR-mediated manner. Hum Immunol 1999; 60:10-19